Comparative Pharmacology
Head-to-head clinical analysis: GASTROVIST versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROVIST versus RENOVUE 65.
GASTROVIST vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrovist (diatrizoate meglumine) is a iodinated radiographic contrast agent that attenuates X-rays, enhancing visualization of the gastrointestinal tract. It acts as a hyperosmolar agent, drawing fluid into the bowel lumen and providing positive contrast for imaging.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
Oral: 50-100 mL of a 30% w/v solution (300 mg iodine/mL) administered orally 30-60 minutes before imaging. Repeat dose if necessary for adequate visualization. Rectal: 100-200 mL of a 30% w/v solution as enema for CT colonography.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (glomerular filtration): >95% of iodinated contrast is excreted unchanged in urine within 24 hours; <5% fecal or biliary.
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent